Company Shanghai Henlius Biotech, Inc.

Equities

2696

CNE100003N76

Pharmaceuticals

Market Closed - Hong Kong S.E. 01:39:00 15/07/2024 pm IST 5-day change 1st Jan Change
22.55 HKD -0.44% Intraday chart for Shanghai Henlius Biotech, Inc. -1.96% +62.23%

Business Summary

Shanghai Henlius Biotech Inc. is a China-based company principally involved in the research, development, production and sales of monoclonal antibody products. The Company’s main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) biosimilar HLX02, Humira (adalimumab) biosimilar HLX03 and Avastin (bevacizumab) biosimilar HLX04, as well as bio-innovative drug candidates, including HLX06 (a novel VEGFR2 inhibitor), HLX07 (an EGFR inhibitor), HLX10 (a novel PD-1 inhibitor), HLX20 (a novel PD-L1 inhibitor) and HLX22 (a novel HER2 inhibitor), among others. The Company is also engaged in the provision of related technical services. The Company operates its businesses primarily in Mainland China and the United States.

Number of employees: 3,637

Sales per Business

HKD in Million2022Weight2023Weight Delta
Biopharmaceutical
100.0 %
3,738 100.0 % 5,961 100.0 % +59.47%

Sales per region

HKD in Million2022Weight2023Weight Delta
China
89.2 %
3,303 88.4 % 5,316 89.2 % +60.92%
North America
5.8 %
169 4.5 % 348 5.8 % +106.21%
Asia Pacific (excluding China)
3.6 %
208 5.6 % 214 3.6 % +3.00%
Europe
1.0 %
58 1.6 % 62 1.0 % +6.83%
South America
0.4 %
-- 21 0.4 % -

Managers

Managers TitleAgeSince
Founder - 01/09/01
Chief Executive Officer 46 30/21/30
President 56 01/20/01
Chairman 57 01/19/01
Chief Tech/Sci/R&D Officer - -
Compliance Officer 41 -
Director/Board Member 39 01/23/01
General Counsel - 13/21/13
Corporate Officer/Principal - -
Corporate Officer/Principal - -

Members of the board

Members of the board TitleAgeSince
Director/Board Member 52 15/13/15
Director/Board Member 53 24/18/24
Director/Board Member 54 12/15/12
Director/Board Member 61 02/19/02
Director/Board Member 52 28/22/28
Director/Board Member 55 -
Chairman 57 01/19/01
Chairman 49 21/20/21
Chief Executive Officer 46 30/21/30
Director/Board Member 39 01/23/01

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 380,066,312 0 0 15.62 %
Stock B 1 163,428,541 84,879,786 ( 51.94 %) 0

Shareholders

NameEquities%Valuation
Henlius Biopharmaceuticals, Inc. /Ky/
26.77 %
43,756,960 26.77 % 128 M $
32,331,100 19.78 % 95 M $
Qatar Holding LLC
6.958 %
11,370,960 6.958 % 33 M $
2,410,695 1.475 % 7 M $
Qatar Investment Authority (Investment Management)
1.031 %
1,684,899 1.031 % 5 M $
720,955 0.4411 % 2 M $
ICBC Credit Suisse Asset Management Co., Ltd.
0.0551 %
90,000 0.0551 % 263 404 $
Jun Zhu
0.0306 %
50,000 0.0306 % 146 336 $
Mackenzie Investments Corp. (United States)
0.003870 %
6,325 0.003870 % 18 511 $
NameEquities%Valuation
291,365,387 80.00 % 853 M $
Jun Zhu
0.0454 %
165,450 0.0454 % 484 224 $
NameEquities%Valuation
Henlink, Inc.
9.715 %
15,876,694 9.715 % 46 M $

Company contact information

Shanghai Henlius Biotech, Inc.

Innov Tower 1801 Hongmei Road, Xuhui District

200233, Shanghai

+

http://www.henlius.com
address Shanghai Henlius Biotech, Inc.(2696)

Sales per region

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
20.96 CNY
Average target price
18.79 CNY
Spread / Average Target
-10.35%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 2696 Stock
  4. Company Shanghai Henlius Biotech, Inc.